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Background Postinflammatory hyperpigmentation (PIH) is a common, acquired
pigmentary disorder of the skin associated with significant quality-of-life impairment, especially in individuals with skin of colour. Current treatment for PIH is
limited, largely due to a poor understanding of disease pathogenesis and the lack
of a representative disease model.
Objectives This study is intended to further develop, update and validate our previously designed in vivo model of acne-induced PIH/postinflammatory erythema
(PIE) using different concentrations of trichloroacetic acid (TCA), a mediumdepth chemical peel.
Methods Twenty-nine patients with skin types II–VI and clinician-confirmed
presence of two or more truncal acne pustules and PIH/PIE were included. On
the basis of Investigator’s Global Assessment (IGA), clinical polarized photography (CPP), colorimetry and Skindex, we experimentally determined an
optimum TCA concentration and assessed our model’s ability to exhibit a
dose–response relationship between degree of inciting insult and severity of
resulting pigmentation. We also performed differential microRNA profiling and
pathway analysis to explore the potential of microRNAs as molecular adjuncts
to our model.
Results Application of TCA 30% produced lesions indistinguishable from acneinduced PIH and PIE lesions on the basis of colorimetry data without causing
epidermal necrosis. Application of progressively increasing TCA doses from
20% to 30% resulted in concentration-dependent increases in CPP, IGA and
colorimetry scores at all timepoints during the study. miRNA-31 and miRNA23b may play a role in PIH pathogenesis, although further validation is
required.
Conclusions Our TCA-based in vivo model, using TCA concentrations between 20%
and 30% with an optimum of 30%, enables the quantitative assessment of the
pigmentary response to varying degrees of cutaneous inflammation in a fashion
that mirrors natural acne-induced PIH and PIE.

© 2021 British Association of Dermatologists
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What is already known about this topic?

•
•

Postinflammatory hyperpigmentation (PIH) is a common, acquired pigmentary disorder of the skin with limited treatment options, largely due to poor understanding
of its underlying pathogenic mechanisms.
Our group previously published an in vivo model of PIH using trichloroacetic acid
(TCA), a medium-depth chemical peel, which resembled naturally occurring acneinduced PIH on the basis of clinical, spectroscopic and histological properties.

What does this study add?

•
•

We further develop, update and validate our previously designed in vivo PIH model
by experimentally determining an optimum TCA dose, and assessing our model’s
ability to exhibit a dose–response relationship between degree of inciting insult
and severity of resulting pigmentation.
We perform differential microRNA profiling on biopsy samples of PIH to explore
the potential of microRNAs as molecular adjuncts to our model.

What is the translational message?

•

We demonstrate the early stages of an accessible, reproducible, in vivo model built
around highly objective methods that span the clinical, optical and molecular characteristics of PIH.

Postinflammatory hyperpigmentation (PIH) is a common,
acquired pigmentary disorder of the skin characterized by
locally reactive hypermelanosis following cutaneous inflammation.1 Inciting events are numerous and include intrinsic causes such as acne vulgaris, contact dermatitis, eczema
and infection, as well as extrinsic causes such as trauma
and surgical procedures. PIH tends to affect patients with
darker skin phototypes (SPTs),2 where insults are typically
followed first by inflammation that evolves into locally
hyperpigmented macules or patches. In lighter skin phototypes, lesions often persist as discrete erythematous macules and are thus termed postinflammatory erythema
(PIE).3
In patients with skin of colour, dyschromic and pigmentary
disorders are among the most cited reasons for dermatological
visits.4 PIH is associated with significantly reduced quality of
life, especially in darker-skinned patients and young adults
with acne vulgaris.4–7 Acne is the most common trigger for
PIH, and its inherent psychosocial burden is greatly amplified
by the high incidence of acne-induced PIH, which takes several months to resolve and is often of greater concern than the
original insult itself.8,9 Despite this burden, management strategies, treatment options and predictive biomarkers for PIH
remain limited.
The pathophysiology of PIH and PIE is only partly
understood, and further insight has been restricted by the
paucity of an in vivo disease model.10 To address this issue,
our group previously developed and validated an in vivo
model of acne-induced PIH/PIE using 35% trichloroacetic
acid (TCA), a medium-depth chemical peel, which was
British Journal of Dermatology (2021)

clinically, histologically and spectroscopically indistinguishable from acne-induced PIH from day 28 onward.11 Resolution of TCA-induced pigmentation, similarly to acneinduced PIH, took weeks to months.11 Further inquiry
demonstrated the importance of uniform gentle application
pressure, equal wait times between passes, and an appropriate concentration of TCA so as not to cause necrosis.12
Our most recent work, utilizing bakuchiol as a PIH treatment modality, was tested using TCA 35% and demonstrated that our TCA-based model allows for controlled
induction of PIH with homogeneous levels of baseline pigmentation and a robust, quantitatively assessable method to
evaluate topical product effectiveness.13
The current study consists of two phases in order to further refine this model. In the first phase, different concentrations of TCA were used to determine the minimum
concentration that induces PIH/PIE most similar to acneinduced PIH without causing necrosis. Then we utilized this
method based on multiple concentrations to show that our
in vivo model can reliably demonstrate a dose–response relationship between the degree of inciting trigger and the
severity of resulting pigmentation. In the second phase, we
investigated microRNAs (miRNAs) for their role in PIH. Well
described in other skin diseases including pigmentary disorders, miRNAs exhibit immense clinical potential but have yet
to be studied within the postinflammatory context. To
address this, we performed differential expression profiling
of tissue miRNAs followed by Ingenuity Pathway Analysis
(IPA) in order to explore the role of these small molecules
as a molecular adjunct to our model.
© 2021 British Association of Dermatologists
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Patients and methods
Patients
This study was approved by the institutional review board of
Henry Ford Hospital (IRB #9920). All guidelines from the
Declaration of Helsinki were followed. Written informed consent was obtained from all patients. Inclusion criteria included
all skin types (type I–VI), age 18 years or older, and
clinician-confirmed presence of two or more truncal acne
pustules and either PIH or PIE. Exclusion criteria included history of melanoma or nonmelanoma skin cancer, keloids, cystic acne, acne conglobata, other pigmentary disorders, recent
tanning bed use, or a recent history of photosensitivity. In
total 30 patients were enrolled. Twenty-nine completed the
study; 20 patients had a tendency to develop PIH and nine of
them had a tendency to develop PIE (Table 1). Tissue specimens from two patients were lost in processing, with specimens from 27 patients included in the miRNA investigations.
In this study, there were no patients with SPT I. The PIH
group comprised individuals with SPT III–VI (one SPT III,
two SPT IV, seven SPT V, and 10 SPT VI). The PIE group
comprised individuals with SPT II–IV (three SPT II, four SPT
III, and two SPT IV).
Study design: clinical polarized photography, colorimetry
and Investigator’s Global Assessment
This was a nonblinded, nonrandomized study similar to our
previous work.11 Patients were recruited at the department of
dermatology of Henry Ford Hospital, Detroit, Michigan. On
day 0, two truncal acne lesions were identified, and TCA was
applied to eight separate circular areas (approximately 05-cm
diameter circular) on either the left or right buttock. Using a
cotton tip applicator, the following concentrations of TCA
were applied to two spots each: 20%, 25%, 30% and 35%.
Applications were made serially, with 30-s intervals, until the

Table 1 Age and sex distribution of the postinflammatory
inflammation (PIH) and postinflammatory erythema (PIE) groups

Age (years)
Mean (SD)
Range
Sex, n
Male
Female
Skin phototype, n
I
II
III
IV
V
VI

PIH (n = 20)

PIE (n = 9)

47 (14)
22–69

31 (10)
22–51

14
6

5
4

0
0
1
2
7
10

0
3
4
2
0
0

© 2021 British Association of Dermatologists

TCA 35% site demonstrated signs of frosting. The same number of passes that resulted in frosting for TCA 35% were used
for the remaining concentrations at those sites. The mean
number of passes for both the PIE and PIH groups was 5 (SD
2). Both truncal acne pustules and TCA-induced lesions were
monitored on days 0, 1, 7, 14, 28 and 35 using the assessment techniques described in the following paragraphs.
Study design: microRNA
For our miRNA exploration, fresh tissue was obtained via a
single 4-mm punch biopsy on visit 5 (day 28) from each of
three sites: truncal acne-induced PIH, gluteal TCA-induced PIH
that clinically resembled acne-induced PIH [as determined
from spectroscopic/colorimetry and Investigator’s Global
Assessment (IGA) scores], and normal skin. Specimens from
two patients were lost in processing. Specimens from two of
the sites, TCA-induced PIH and normal skin, were included
for a total of 54 fresh tissue samples from 27 patients. After
tissue homogenization, extraction of small RNAs was accomplished using the Exiqon miRCURY RNA Isolation Kit (Qiagen, Venlo, the Netherlands). The quantity, integrity and
purity of the RNA samples were evaluated using NanoDrop
(Thermo Fisher Scientific Inc., Waltham, MA, USA) and Qubit
Fluorometer (Invitrogen, Carlsbad, CA, USA). If the quantity
of RNA was below 350 ng, preamplification according to the
manufacturer’s protocol was done in order to accumulate adequate starting material for downstream analyses.
Initial screening was accomplished using the TaqMan
Advanced miRNA Array A+B Card Sets (Thermo Fisher),
which enables quantification of 754 microRNAs. The A and B
cards differ in that a small portion of microRNAs (˜5%) is
assessed by only one card or the other, while the vast majority
are covered by both. Two separate but similar protocols, both
from TaqMan, were carried out due to the availability of array
cards. These protocols were termed protocol 1 and protocol 2,
and the main differences between the two were that protocol
1 uses universal reverse-transcriptase primers and has a higher
sensitivity and specificity, reflected in the increased number of
detected miRNAs at a lower average Ct value. Quantitative
reverse-transcriptase polymerase chain reaction (qRT-PCR) was
performed using the QuantStudio 12K Flex qRT-PCR system
(Thermo Fisher).
Clinical polarized photography
Clinical photographs of truncal acne and gluteal TCA-induced
lesions were captured at each visit.
Investigator’s Global Assessment of pigmentation and
erythema
The degrees of pigmentation and erythema at each site were
graded using an Investigator’s Global Assessment scale for
hyperpigmentation and erythema (Table 2). In addition, a
document containing photographs for all visits related to a
British Journal of Dermatology (2021)
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Table 2 Investigator’s Global Assessment (IGA) scores for
hyperpigmentation and erythema used for clinician evaluation of
lesions
IGA

Description

0
1
2
3
4
5

Clear of hyperpigmentation
Almost clear of hyperpigmentation
Mild but noticeable hyperpigmentation
Moderate hyperpigmentation (medium brown in quality)
Severe hyperpigmentation (dark brown in quality)
Very severe hyperpigmentation (very dark brown, almost
black in quality)

given patient was compiled, and two raters independently performed IGA scoring on these images.
Colorimetry
Colorimetry is a noninvasive, objective assessment tool that
helps to quantify the degree of pigmentation and erythema.
Colorimetric analysis measured the change in the L* parameter
(ΔL*), which corresponds to relative hyperpigmentation, with
increased pigmentation corresponding to a negative ΔL* value.
Change in colorimetry a* (Δa*) parameter was also measured,
which corresponds to relative erythema. It was calculated by
subtracting the a* value of the adjacent normal skin from that
of the lesion site. An increase in erythema would result in an
increase or positive value of Δa*. Each patient acted as their
own control as sites were normalized against their own nonlesional skin.

and each of the TCA concentrations on day 28 using one-way
repeated-measures ANOVA. If significant differences were identified, a Tukey test was then performed to identify specific pairs
that were significantly different. P-values < 005 were considered statistically significant. All analyses were done using OriginPro software (version 9.1.0; OriginLab Corporation,
Northampton, MA, USA).
MicroRNA expression profiling
TCA-induced PIH skin samples were compared with normal
skin samples from all 27 patients with viable tissue. Global
normalization was performed against a built-in reference, stably expressed endogenous miRNA to control for variations in
the amount of starting material, quality control and preparation methods. We accomplished further analyses using MetaboAnalyst 30,15 adjusted for statistical discrimination. A
paired t-test for matched samples was performed with several
P-values generated, and an alpha-criterion of 005 was defined
as the upper threshold. To control the effect of multiplicity
and reduce the probability of type I error, P-values were
adjusted for multiple comparison procedures using the R
package multtest (R Foundation, Vienna, Austria) and the
method of Benjamini and Hochberg,16 resulting in an adjusted
false discovery rate. These results are summarized in Table 4.
Clustering and classification discrimination were accomplished
by principal component analysis (PCA) and partial least
squares discriminant analysis (PLS-DA).17 The resulting score
plots show a projection of high-dimensional data into two to
three dimensions in a way that explains the maximal variance
(PCA) or covariance (PLS-DA). Variable importance in projection (VIP), an estimation of the importance of each variable in
the PLS-DA model, was also computed.

Skindex-16
After screening, patients completed Skindex-16, a seven-point,
validated, single-page patient-reported outcome instrument
that measures the effect of skin disease on emotional, functional and symptom-related quality of life.14 The highest score
possible is 96 (Table 3).
Statistical analysis
IGA scores for hyperpigmentation and erythema and change
in colorimetry parameters were compared between acne sites
Table 3 Mean Skindex-16 subscale scores

Total
Symptoms score
Emotions score
Functioning score

Ingenuity Pathway Analysis (IPA; Qiagen) was used to identify
experimentally validated and highly predicted target mRNAs
of differentially expressed miRNAs. IPA functions are derived
from TargetScan, miRecords, TarBase and Ingenuity Expert
Findings, which contain data from experimentally validated
publications and associated prediction scores (i.e. in silico, PolyPhen). Select miRNAs were then inputted into the Ingenuity
Knowledge Base (Ingenuity Systems, Redwood City, CA, USA)
to reconstruct potential pathways of relevance.

Results

Maximum possible score

Mean (SD) score

96
24
42
30

42
8
26
9

(24)
(5)
(4)
(9)

Skindex-16 is a patient-reported outcomes instrument that measures the effect of skin disease on quality of life.14

British Journal of Dermatology (2021)

Target prediction and network analysis

Patients
In total, 29 (19 male, 10 female) of the 30 enrolled patients
completed the study. Tissue samples from 27 (17 male, 10
female) were included in the microRNA analysis. Twenty
patients had truncal acne with PIH, while nine had truncal
acne with PIE. The demographic characteristics of patients are
summarized in Table 1.
© 2021 British Association of Dermatologists
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Table 4 Results of differential microRNA profiling by MetaboAnalyst workflow
miRNA
miR-31-5p
miR-323a-3p
miR-495-3p
miR-135b-5p
miR-127-3p
miR-615-3p
miR-380-3p
miR-21-5p
miR-433-3p
miR-885-5p
miR-422a
miR-26a-5p
miR-382-5p
miR-197-3p
miR-570-3p
miR-23b-3p
miR-331-5p
miR-889-3p
miR-31-3p
miR-409-3p
miR-432-5p

P-value
255 9
370 9
154 9
159 9
228 9
243 9
722 9
00001
00002
00003
00009
00015
00027
00029
00040
00044
00058
00061
139 9
140 9
0001

7

10
106
105
105
105
105
105

107
106

FDR

Mean HC

Mean PIH

DDCT (PIH  HC)

FC

00001
00003
00008
00008
00009
00009
00023
00031
00035
00050
00091
0015
0022
0024
0029
0031
0036
0037
144 9 105
726 9 105
0018

252
647
331
452
082
397
598
350
463
454
254
489
438
297
577
470
881
391
101
213
048

082
523
268
322
009
333
510
420
387
529
383
422
349
210
666
254
781
276
207
314
035

335
124
064
131
073
064
089
070
076
075
130
067
089
087
090
216
100
116
308
101
083

102
236
155
247
166
156
185
162
170
169
246
159
185
182
186
447
200
223
845
201
178

FC, fold change; FDR, false discovery rate; HC, unaffected healthy control skin; PIH, postinflammatory inflammation.

Figure 1. Representative photographs of truncal acne (bottom row) and trichloroacetic acid (TCA)-induced lesions (top four rows) with time
course of postinflammatory inflammation development.

Clinical polarized photography and Investigator’s Global
Assessment
Representative clinical photos across all timepoints and concentrations of TCA are shown in Figure 1. Changes in IGA scores
for hyperpigmentation (Figure 2a) and erythema (Figure 2b)
© 2021 British Association of Dermatologists

are shown for the PIH and PIE groups, respectively. Day 28
IGA scores for hyperpigmentation showed no statistically significant differences between acne and TCA concentrations of
25%, 30% and 35% (Figure 2c). Day 28 IGA scores for erythema showed no statistically significant differences between
acne and any of the TCA concentrations (Figure 2d).
British Journal of Dermatology (2021)
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Time (Days)

Time (Days)

3
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–2

–1

0

1

2

3

Figure 2. (a, b) Change in Investigator’s Global Assessment (IGA) scores at acne sites and with different concentrations of trichloroacetic acid
(TCA) as a function of time for (a) hyperpigmentation in the postinflammatory inflammation (PIH) group and (b) erythema in the
postinflammatory erythema (PIE) group. (c, d) Tukey test comparison between IGA scores of acne sites and all TCA concentrations on day 28 for
(c) hyperpigmentation in the PIH group and (d) erythema in the PIE group.

Day 28 was used in the Tukey test comparison, because in
previous experiments, IGA hyperpigmentation scores for acne
and TCA lesions converged and were closely matched from
day 28 after application onwards.11 At all timepoints during
the study, greater degrees of both pigmentation and erythema
were observed with progressively increasing concentrations of
TCA on the basis of CPP and IGA (Figure 2a, b).
Colorimetry
Figure 3(a, b) shows the changes in relative hyperpigmentation (ΔL*) and relative erythema (Δa*) for acne and all concentrations of TCA investigated for the PIH and PIE groups,
respectively. Day 28 IGA scores for hyperpigmentation showed
no statistically significant differences between acne and TCA
concentrations of 30% and 35% (Figure 3c). Day 28 IGA
scores for relative erythema demonstrated no statistically significant differences between acne and TCA 30% and 35%
(Figure 3d). Greater degrees of both pigmentation and erythema were observed on colorimetry with progressively
British Journal of Dermatology (2021)

increasing concentrations of TCA at 20%, 25% and 30%
throughout the duration of the study (Figure 3a, b). A concentration of 35% gave lower results than 30%; however, as
this work indicates, 35% causes necrosis and thus will not be
used with this model.
Skindex-16
The results of Skindex-16 administration are shown in
Table 3. Mean scores on the symptoms, emotions and functioning scales were 8, 26 and 9, respectively, and the mean
total score was 42.
Microarray analysis demonstrates differential expression
of tissue miRNAs
Using an initial cycle threshold (Ct) cutoff of < 40, each individual expressed an average of 280 and 171 miRNAs in TaqMan array cards A and B, respectively. Transcripts were then
filtered by those expressed in > 80% of all samples, leaving
© 2021 British Association of Dermatologists
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Figure 3. (a, b) Change in colorimetry parameters for acne sites and different concentrations of TCA as a function of time for (a)
hyperpigmentation in the postinflammatory inflammation (PIH) group (relative hyperpigmentation, ΔL*) and (b) erythema in the
postinflammatory erythema (PIE) group (relative erythema, Δa*). (c, d) Tukey test comparison among change in colorimetry parameters for acne
sites and all trichloroacetic acid (TCA) concentrations on day 28 for (c) hyperpigmentation in the PIH group (ΔL*) and (d) erythema in the PIE
group (Δa*).

255 and 104 miRNAs in cards A and B, respectively. Pairwise
comparison of TCA-induced PIH (TIP) vs. normal skin (NS)
revealed 21 miRNAs with significantly differential expression
based on fold change > 15 with false discovery rate < 005
and P < 005.16,18 Fifteen miRNAs were upregulated and six
were downregulated (Table 4). Fold change had moderate
single-digit variance, with notable fold changes of 102, 845
and 447 for miR-31-5p, miR-31-3p and miR-23b-3p,
respectively. Hierarchical cluster analysis in a heatmap displays
rough separation of TIP and NS (Figure 4b).
Cluster analysis mapped onto PCA projection reveals further,
clear separation of the TIP and NS groups with homogeneous
clustering within each group (Figure 4a).15 Data points that
appear on the left side of the PCA plot are similar in that they
all used protocol 1, while those on the right used protocol 2
(see Study design). While this is an unfortunate limitation and
may explain the intragroup differences, the clear clustering of
TCA-induced PIH from unaffected skin within samples using
© 2021 British Association of Dermatologists

the same protocol (protocol 1 or 2) provided an opportunity
for validation by revealing separation between the two groups
when studied using two independent protocols (Figure 4a).
The fact that cumulative analysis of all samples (using protocols 1 and 2) also demonstrated clear clustering of the two
groups (TCA-induced PIH and unaffected skin), despite the
use of two different protocols, further supports our results.
PLS-DA-based variable importance in projection (VIP) scores
are displayed to estimate the relative importance of each
miRNA transcript (Figure 4c, d). Those with a VIP value > 1
were included. miR-31 and miR-23b demonstrated the highest
VIP scores.
Ingenuity Pathway Analysis reveals potentially involved
cellular pathways
The 21 differentially expressed miRNAs were first analysed for
their experimentally validated target gene transcripts (mRNAs).
British Journal of Dermatology (2021)
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(a)

(b)

(c)

(d)

Figure 4. (a) Principal component analysis (PCA) of the microRNA expression dataset from tissue biopsy samples of trichloroacetic acid (TCA)induced postinflammatory inflammation (PIH, blue) and unaffected healthy control skin (HC, red). (b) Heatmap with separation by group
illustrating levels of changed expression in microRNAs that reached significance (fold change > 15, P < 001). (c, d) Variable of importance
projections (VIP) scores for array cards A (c) and B (d).

The resulting gene list was then used for IPA analysis of
canonical pathways, disease biofunctions and networks
(Figure 5 and Table 5). miRNAs with the greatest fold change
(miR-31-5p and miR-31-3p) were separately analysed for
gene-network connectivity through Ingenuity Knowledge Base,
with experimentally validated relationships overlaid with
highly predicted relationships (Figure 5).

Discussion
The mechanisms contributing to PIH, while only partially
understood, are thought to centre around the paracrine crosstalk between keratinocytes and melanocytes, whereby injurious stimuli jumpstart keratinocyte production of eicosanoids
British Journal of Dermatology (2021)

and several other soluble factors that trigger local melanocytes
to increase the production of melanin.2,19,20 Melanin is then
transferred to surrounding keratinocytes in the epidermis or
engulfed by macrophages in the dermis, manifesting as two
histopathological forms of PIH – epidermal and dermal,
respectively – that can be observed clinically.2 The complexity
of this process is reflected by the clinical variability of PIH/
PIE, which depends on the mechanism of the causative insult,
which must then be parsed out of the subsequent pigmentary
response, as well as genetic and immunological factors.
Addressing this concern requires the use of validated disease
models that exhibit high specificity and sensitivity; are noninvasive, reproducible and accessible; and can reliably distinguish between stages or subtypes of disease. Several in vitro
© 2021 British Association of Dermatologists
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(a)

(b)

(c)

Figure 5. Interactome of highly differential microRNAs. (a) Pathway analysis of miR-31-5p and common seed sequences. Experimentally validated and
highly predicted gene/messenger RNA targets are first identified and then subjected to pathway analysis to demonstrate gene-network connectivity.
Pathways involving formation of skin and keratinization of epidermis are prominent. (b) Pathway analysis of miR-31-3p and common seed sequences.
Pathways involving cutaneous melanoma are prominently overlapping. (c) Example subcellular processes affected by involved pathways.

© 2021 British Association of Dermatologists
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Table 5 Summary of enriched pathways for messenger RNA/gene
targets of all 21 differentially expressed microRNAs (experimentally
validated only)
Name

P-value range

Molecular and cellular functions
Cellular development
260 9 106 to
244 9 1027
Cellular growth
241 9 106 to
and proliferation
244 9 1027
Cell death and survival
208 9 106 to
169 9 1023
Cellular movement
157 9 106 to
316 9 1020
Gene expression
825 9 109 to
801 9 1019
Physiological system development and function
204 9 106 to
Connective tissue
development
267 9 1016
and function
Tissue development
241 9 106 to
267 9 1016
Organismal support
921 9 1012 to
567 9 1014
Tissue morphology
226 9 106 to
123 9 1011

# molecules
63
63
60
49
53

28

34
31
18

models for studying human skin pigmentation have been
devised,21–23 but these fall short in replicating the dynamics
of in vivo skin.
In our previous study,11 we compared acne-induced PIH
against 35% TCA-induced PIH, a concentration that also
caused epidermal necrosis and impeded assessment. To address
this, in this study we applied TCA concentrations of 20%,
25%, 30% and 35% to determine a lower dose that accurately
represented acne-induced PIH without causing necrosis.
Although clinical IGA scores for hyperpigmentation (Figure 2)
showed a change in acne and TCA-induced hyperpigmentation, with an earlier onset and potential decrease at day 35 for
acne, objective colorimetry L* data (Figure 3a) showed similarity between TCA and acne-induced hyperpigmentation over
time. The change in trend assessed via clinical scoring, as
such, could be attributed to the discrete nature of this assessment technique. At day 28, TCA concentrations of 30% and
35% were indistinguishable from acne-induced PIH, and a*
data showed that these were indistinguishable from acneinduced PIE (Figure 2).
In a dose–response study, application of 20%, 25% and
30% TCA resulted in progressively increasing CPP, IGA and
colorimetry scores in a concentration-dependent manner
(Figures 2a, b and 3a, b). This differential response was
clearly observed by the separation of the corresponding line
graphs in each figure, maintained at all timepoints during the
study, and was true for both the hyperpigmentation and erythema groups. Given that colorimetry of 35% TCA did not follow this pattern, likely due to its induction of necrosis, we
recommend TCA concentrations between 20% and 30% with
British Journal of Dermatology (2021)

an optimum of 30% for acne-induced PIH, and have demonstrated its potential in assessing product effectiveness using
bakuchiol.13 The ability to noninvasively, quantitatively assess
the relationship between the degree of inflammation and the
extent of pigmentary response in vivo is vital to dissect the
mechanisms that link inflammation and pigmentation.24
In the second phase of this work, differential miRNA profiling of TCA-induced PIH lesions vs. normal skin was performed. miRNAs are short, noncoding RNAs that bind mRNAs
at the 30 -untranslated region and negatively regulate gene
expression via silencing or degradation.25 miRNAs are highly
stable, well conserved and easily detectable,26 and thus are
especially attractive as therapeutic targets and biomarkers in an
in vivo model of a melanocyte-centric disease with a likely
polygenic influence.
To our knowledge, this is the first study assessing miRNAs
in PIH or PIE. After quality control, normalization and analysis, we identified 21 differentially expressed miRNAs between
TCA-induced PIH and normal skin (Table 4). These results are
bolstered by PCA analysis (Figure 4), which demonstrated
clear separation of the TCA-induced PIH group (blue) and
normal skin (red). miR-31-5p, miR-31-3p and miR-23b-3p
expressed notably higher absolute fold changes at 102, 845
and 447, respectively, and higher VIP scores than the other
miRNAs identified.
miR-31 is markedly overexpressed in keratinocytes of psoriasis and discoid lupus skin,27 and has a previously identified
role in keratinocyte development and mediation of innate
immunity.28 Specifically, miR-31 represses protein phosphatase 6 to enhance keratinocyte proliferation and silences serine/threonine kinase 40, a negative regulator of nuclear factor
(NF)-jB signalling in keratinocytes, thus promoting NF-jBmediated cytokine release.29 Given that NF-jB is central to the
generation of eicosanoids, which have been implicated in the
pathogenesis of PIH,19 these data propose a pathway by which
miR-31 overexpression may contribute to the pathophysiology
of PIH.
Furthermore, miR-31 has minimal expression in nondiseased skin and in nonkeratinocyte skin cells, increasing its
specificity as a distinguishing biomarker.30 Similarly, miR-23b
is highly expressed in and serves as an in vivo differentiation
biomarker for keratinocytes,31 and has been shown to have a
potent anti-inflammatory role in tissue-resident cells through
its inhibitory actions on NF-jB.18,32 Therefore, its decreased
expression observed in our study is not surprising, and is consistent with downregulation of miR-23b in immune-mediated
conditions such as lupus and rheumatoid arthritis.18
Subsequent IPA analysis showcases enrichment of pathways
involving cellular and tissue injury, survival, growth and development (Table 5), as well as an interactome that links miR-315p and miR-31-3p with skin formation and cutaneous
melanoma, respectively. miR-340, miR-145, miR-125b and
miR-211 have previously been identified as being involved specifically in the pigmentary process,33–36 and microphthalmiaassociated transcription factor, the central epigenetic regulator
of pigmentation, appears to be targeted by the latter three.37,38
© 2021 British Association of Dermatologists
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A few limitations are present in our study. Firstly, IGA scoring
is not a validated instrument. In addition, while the postacne
hyperpigmentation index, PAHPI, is validated for PIH, it is only
generalizable to African American women due to the population
of the validation study.39 Histological examination was not
done in this study because our previous study indicated no
significant differences among groups,11 and because the colourbased methods employed here have the advantage of being noninvasive and in vivo while remaining objectively validated and
clinically reproducible. A critique of our original TCA-based
approach cited the potential for uncontrolled necrosis as a limitation, which is circumvented by our proposed maximum concentration of 30% TCA. An alternative method using suction
blisters was proposed.40 However, while it is feasible, the TCAbased method is less costly and more easily reproduced and does
not require specialized equipment. Importantly, the lack of
experimental validation in our miRNA analysis and the fact that
we did not assess miRNA expression in acne-induced PIH are
two key limitations in our study; these will be our goals in
future studies. Another worthwhile comparison is with in vivo
miRNA data from acne lesions without PIH, data that have yet
to be explored outside of two works that tenuously link a select
few miRNAs to acne.41
In summary, we establish our previously validated TCA-based
technique as a representative model for acne-induced PIH, and
propose TCA 30% as the optimum concentration to apply. This
model can reliably demonstrate a dose–response relationship
between the degree of an inflammatory trigger and the severity
of the resulting pigmentary response, which could serve as the
backbone of future assays designed for topical therapeutics. We
also explore the potential of miRNAs as an adjunctive molecular
tool to our clinical model, demonstrating promising results that
identify miR-31 and miR-23b as potential candidate markers
and therapeutic targets. Together, these results demonstrate the
early stages of an accessible, reproducible, in vivo model built
around highly objective methods that span the clinical, optical
and molecular characteristics of PIH.
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